Table 3

Multivariate-adjusted ORs and 95% CIs between asymptomatic intracranial arterial stenosis and diabetic parameters of the total participants and as per sex

In all participants (n=2007)In male participants (n=957)In female participants (n=1050)
OR (95% CI)P valueOR (95% CI)P valueOR (95% CI)P value
DM*
 Model 12.52 (1.61 to 3.92)<0.0014.11 (2.04 to 8.28)<0.0011.88 (1.05 to 3.36)0.034
 Model 22.09 (1.31 to 3.32)0.0023.40 (1.62 to 7.13)0.0011.53 (0.83 to 2.79)0.170
FPG†, mmol/L
 Model 11.41 (1.21 to 1.64)<0.0011.75 (1.37 to 2.24)<0.0011.24 (1.02 to 1.52)0.034
 Model 21.34 (1.14 to 1.57)<0.0011.64 (1.26 to 2.13)<0.0011.18 (0.96 to 1.47)0.124
HOMA-IR†
 Model 11.50 (1.20 to 1.86)<0.0011.61 (1.16 to 2.22)0.0041.41 (1.04 to 1.90)0.026
 Model 21.24 (0.97 to 1.59)0.0831.39 (0.96 to 2.02)0.0841.12 (0.81 to 1.55)0.484
IR*
 Model 12.32 (1.52 to 3.54)<0.0013.69 (1.85 to 7.33)<0.0011.76 (1.03 to 2.99)0.038
 Model 21.75 (1.11 to 2.75)0.0153.04 (1.44 to 6.42)0.0041.25 (0.71 to 2.20)0.441
  • Model 1: adjusted for age, gender, smoking habit, drinking habit, and LDL-C (continuous variable).

  • Model 2: Adjusted for variables in model 1 plus additional metabolic syndrome components (raised blood pressure (dichotomous variable), triglycerides (continuous variable), HDL-C (continuous variable), and waist circumference (continuous variable)).

  • *The ORs of dichotomous variables were for those with the feature when taking those without as reference.

  • †The ORs of continuous variables were for 1-SD increase after logarithmic transformation.

  • DM, diabetes mellitus; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; IR, insulin resistance (HOMA-IR ≥3.0); LDL-C, low-density lipoprotein cholesterol.